This site uses cookies to measure how you use the website so it can be updated and improved based on your needs and also uses cookies to help remember the notifications you’ve seen, like this one, so that we don’t show them to you again. If you could also tell us a little bit about yourself, this information will help us understand how we can support you better and make this site even easier for you to use and navigate.

Sertraline for the treatment of depression in Alzheimer disease


Rosenberg, Paul B., Drye, Lea T., Martin, Barbara K., Frangakis, Constantine, Mintzer, Jacobo E., Weintraub, Daniel, Porsteinsson, Anton P., Schneider, Lon S., Rabins, Peter V., Munro, Cynthia A., Meinert, Curtis L., Lyketsos, Constantine G.


The American Journal Of Geriatric Psychiatry: Official Journal Of The American Association For Geriatric Psychiatry, Volume: 18, No.: 2, Pages.: 136-145

Year of Publication



Objective: Depression is common in Alzheimer disease (AD), and antidepressants are commonly used for its treatment, however, evidence for antidepressant efficacy in this population is lacking. The authors conducted a multicenter, randomized, placebo-controlled trial titled “Depression in Alzheimer’s Disease-2” to assess the efficacy and tolerability of sertraline for depression in AD.; Methods: One hundred thirty-one participants from five U.S. medical centers with mild-to-moderate AD (Mini-Mental State Examination scores 10-26) and depression of AD were randomized to double-blinded treatment with sertraline (N = 67) or placebo (N = 64), with a target dosage of 100 mg daily. Efficacy was assessed using logistic regressions and mixed effects models in an intention-to-treat analysis with imputation of missing data. Principal outcome measures were modified Alzheimer’s Disease Cooperative Study-Clinical Global Impression of Change (mADCS-CGIC), change in Cornell Scale for Depression in Dementia (CSDD) scores, and remission defined by both mADCS-CGIC score

Bibtex Citation

@article{Rosenberg_2010, doi = {10.1097/jgp.0b013e3181c796eb}, url = {}, year = 2010, month = {feb}, publisher = {Elsevier {BV}}, volume = {18}, number = {2}, pages = {136--145}, author = {Paul B. Rosenberg and Barbara K. Martin and Constantine Frangakis and Jacobo E. Mintzer and Daniel Weintraub and Anton P. Porsteinsson and Lon S. Schneider and Peter V. Rabins and Cynthia A. Munro and Curtis L. Meinert and Constantine G. Lyketsos and Lea T. Drye}, title = {Sertraline for the Treatment of Depression in Alzheimer Disease}, journal = {The American Journal of Geriatric Psychiatry} }


adverse, adverse effects, aged, alzheimer disease, complications, depression, double-blind method, drug therapy, events, female, humans, male, medication adherence, patient dropouts, placebos, serotonin uptake inhibitors, sertraline, statistics & numerical data, therapeutic use, treatment outcome

Countries of Study


Types of Dementia

Alzheimer’s Disease

Types of Study

Randomised Controlled Trial

Type of Outcomes

Cognition, Depression and Anxiety, Other

Type of Interventions

Pharmaceutical Interventions

Pharmaceutical Interventions

Antipsychotics and antidepressants